Selpercatinib与交叉治疗困境:进展后治疗对总生存期解读的潜在影响
本文讨论LIBRETTO-431试验中selpercatinib对比含铂化疗±帕博利珠单抗治疗初治RET融合阳性NSCLC,虽PFS大幅改善但OS分析不成熟且HR为1.26 favoring化疗免疫组,强调高交叉率和多变进展后治疗使OS解读困难,需预设数据收集与分析方法。
要点
- 随机试验中即使OS非主要终点也应评估,因其反映安全性和疗效。
- LIBRETTO-431中selpercatinib的PFS大幅改善但OS不成熟,HR 1.26 favoring化疗免疫组。
- 高交叉率和可变进展后治疗使OS解读复杂,需预设分析计划。
核心结论
- 在高交叉率和可变进展后治疗的试验中解读OS具有挑战性。
- 无论OS在终点层级中的位置如何,OS分析都应包括预设的数据收集和分析方法以考虑进展后治疗的影响。
研究设计与样本
- LIBRETTO-431为外美国多区域、开放标签、随机、活性对照试验,比较selpercatinib与含铂和培美曲塞化疗±帕博利珠单抗。
- 研究对象为初治晚期RET融合阳性非小细胞肺癌患者。
主要发现
- selpercatinib组PFS大幅改善且安全性可接受。
- OS分析不成熟,风险比为1.26, favoring化疗免疫治疗组。
临床怎么用
- 在随机试验中应评估OS,即使不是主要终点。
- 设计试验时应预设进展后治疗的数据收集和分析方法以辅助OS解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Overall survival (OS) should be evaluated in all randomized cancer trials, even when not the primary end point, as it is clinically meaningful and measures both safety and efficacy. Crossover from the control to experimental arms in randomized trials may be incorporated to allow access to promising investigational treatments after progression on a control arm. The results of Study LIBRETTO-431, an ex-US multiregional, open-label, randomized, active-controlled trial of selpercatinib versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with treatment-naïve advanced rearranged during transfection fusion-positive non-small cell lung cancer, highlight the challenges of interpreting OS in trials with high crossover rates and variable postprogression therapies. Trial results demonstrated a large improvement in progression-free survival with an acceptable safety profile, but were accompanied by an immature OS analysis with a hazard ratio of 1.26, favoring the chemoimmunotherapy arm. Regardless of the position of OS in the end point hierarchy, it is critical that OS analyses include prespecified plans for data collection and analytical methods to account for the potential impact of postprogression therapies on the interpretation of study results.
引用
- Duke ES, Bradford D, Sinha AK, et al. Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. J Clin Oncol. 2026. PMID: 41996652. doi:10.1200/JCO-25-02375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。